Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Debt / DBCV 1.500%11/1
-
Market price (% of par)
-
146.45%
-
Total 13F principal
-
$553,703,000
-
Principal change
-
-$2,069,000
-
Total reported market value
-
$810,954,622
-
Number of holders
-
37
-
Value change
-
-$3,830,280
-
Number of buys
-
10
-
Number of sells
-
29
Institutional Holders of SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 as of Q4 2021
As of 31 Dec 2021,
SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 was held by
37 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$553,703,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, DeepCurrents Investment Group LLC, WOLVERINE ASSET MANAGEMENT LLC, LORD, ABBETT & CO. LLC, D. E. Shaw & Co., Inc., Allianz Asset Management GmbH, BAKER BROS. ADVISORS LP, Verition Fund Management LLC, CALAMOS ADVISORS LLC, and STATE STREET CORP.
This page lists
37
institutional bondholders reporting positions
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.